Developments in the systemic treatment of metastatic cervical cancer
Cancer Treatment Reviews, 06/29/2012
Mountzios G et al. – Cisplatin has been also combined with a number of agents including paclitaxel, topotecan, gemcitabine, vinorelbine and ifosfamide, leading to encouraging response rates and increases in progression–free survival in a series of randomized phase III trials. Platinum–based triplets have been also tested, albeit at the cost of substantial toxicity. More recently, combinations with molecular agents targeting critical pathways in cervical malignant transformation are being assessed in clinical trials.
